ClearPoint Neuro, Inc. (filed as MRI Interventions, Inc.) — Q1 2017 Form 10-Q
Business context and period: The filing covers the three months ended March 31, 2017, with comparisons to Q1 2016. The company develops and sells MRI-guided minimally invasive surgical technology. Its commercial business is principally the ClearPoint system for neurological procedures; ClearTrace, a cardiac product candidate, remained suspended and was not approved for commercial sale.
Key financial results
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Total revenue | $2.007 million | $1.394 million; up 44% |
| Product revenue | $1.922 million | $1.366 million |
| Operating loss | $1.354 million | $1.934 million |
| Net loss | $1.656 million | $2.044 million; loss narrowed 19% |
| Basic and diluted loss per share | $0.46 | $0.89 |
| Operating cash flow | $(1.346) million | $(1.609) million |
| Cash and cash equivalents at period end | $1.970 million | $3.316 million at Dec. 31, 2016 |
| Current assets / current liabilities | $4.884 million / $3.226 million | At March 31, 2017 |
| Total liabilities / stockholders’ deficit | $8.396 million / $(2.205) million | At March 31, 2017 |
Performance, debt and liquidity
- Disposable ClearPoint sales increased 51% to $1.7 million, primarily reflecting more procedures. Reusable product sales were approximately $259,000, essentially flat. Price increases were limited.
- Gross margin on product revenue improved to 61% from 49%, which management attributed mainly to product mix and production efficiencies.
- Research and development expense declined 15% to $558,000. Selling, general and administrative expense increased 4% to $2.051 million, including higher compensation, recruiting and professional fees.
- Interest expense declined 38% to $213,000 following debt reductions and conversions. A $93,000 derivative fair-value loss in Q1 2017 contrasted with a $160,000 gain in Q1 2016, partly offsetting the lower interest expense.
- Debt includes a $2.0 million senior secured Brainlab note due December 2018, plus junior secured notes. Scheduled principal payments total $6.975 million in 2018–2020; carrying amounts are reduced by unamortized discounts and financing costs.
- No cash investing or financing activity occurred in Q1 2017. Cash used in operations was $1.346 million, and cash fell by the same amount during the quarter.
Outlook, risks and notable items
- Management expected revenue growth over the next 12 months from increased use at existing sites and installations at new sites, while expecting continuing operating cash consumption. No quantified revenue or earnings guidance was provided.
- The company stated that additional financing would be necessary and that it might not be available on acceptable terms or in sufficient amounts. The filing explicitly reported substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the financial statements.
- Potential equity financing could dilute existing shareholders. Failure to obtain financing could prevent the company from achieving its plans or meeting obligations as due.
- Key risks include uncertain adoption of ClearPoint, competition and technological change, dependence on suppliers and key personnel, regulatory requirements, and product liability. Two customers represented 33% of accounts receivable at March 31, 2017; one customer contributed 12% of product revenue.
- The filing reported no material change to previously disclosed risk factors, no legal proceedings, and effective disclosure controls. It listed an April 25, 2017 license and collaboration agreement with Acoustic Medsystems; the supplied filing text does not describe its terms or financial impact.
Important facts for investors to verify
- Cash runway and timing, terms, and availability of the additional financing management says is necessary.
- Whether ClearPoint procedure growth and new-site installations continue to support recurring disposable sales and the improved gross margin.
- Debt repayment and interest obligations, including the scheduled 2018–2020 principal maturities and secured-note terms.
- The terms and potential financial or strategic impact of the April 25, 2017 Acoustic Medsystems agreement.
- Customer concentration, supplier availability, and the status of ClearTrace, whose development was suspended.